Holen Sie sich die Stockscreener-App
382.35
0.52%
1.96
Handel nachbörslich:
382.37
0.02
+0.01%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SYK?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$380.39
Offen:
$381.28
24-Stunden-Volumen:
840.22K
Relative Volume:
0.53
Marktkapitalisierung:
$146.12B
Einnahmen:
$23.22B
Nettoeinkommen (Verlust:
$2.86B
KGV:
51.67
EPS:
7.4
Netto-Cashflow:
$3.58B
1W Leistung:
+1.08%
1M Leistung:
+3.08%
6M Leistung:
-2.50%
1J Leistung:
+12.08%
1-Tages-Spanne:
$378.48
$384.66
1-Wochen-Bereich:
$371.26
$385.40
52-Wochen-Spanne:
$314.93
$406.19
Stryker Corp Stock (SYK) Company Profile
Firmenname
Stryker Corp
Sektor
Branche
Telefon
(269) 385-2600
Adresse
1941 STRYKER WAY, PORTAGE, MI
Vergleichen Sie SYK mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SYK
Stryker Corp
|
382.35 | 144.57B | 23.22B | 2.86B | 3.58B | 7.40 |
|
ABT
Abbott Laboratories
|
132.85 | 228.79B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
104.50 | 154.60B | 17.55B | 2.03B | 2.72B | 1.37 |
|
MDT
Medtronic Plc
|
82.41 | 103.72B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
77.73 | 43.87B | 5.54B | 4.18B | 623.10M | 7.00 |
Stryker Corp Stock (SYK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-26 | Fortgesetzt | Citigroup | Buy |
| 2024-12-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-09-10 | Eingeleitet | Wolfe Research | Outperform |
| 2024-05-30 | Eingeleitet | Goldman | Neutral |
| 2024-05-22 | Hochstufung | Needham | Hold → Buy |
| 2024-01-31 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2023-10-20 | Eingeleitet | ROTH MKM | Buy |
| 2023-09-05 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-03-29 | Eingeleitet | UBS | Neutral |
| 2023-01-25 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2023-01-09 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-11-01 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-07-28 | Hochstufung | Edward Jones | Hold → Buy |
| 2022-07-21 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2022-07-11 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-04-13 | Eingeleitet | Truist | Hold |
| 2022-03-16 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2022-03-15 | Fortgesetzt | Evercore ISI | Outperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-01-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-01-04 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2021-12-07 | Eingeleitet | Loop Capital | Buy |
| 2021-09-14 | Fortgesetzt | Raymond James | Mkt Perform |
| 2021-07-28 | Hochstufung | Northland Capital | Market Perform → Outperform |
| 2021-06-01 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2021-05-25 | Eingeleitet | Barclays | Underweight |
| 2020-10-06 | Eingeleitet | Northland Capital | Market Perform |
| 2020-09-11 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-04-13 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2020-04-01 | Herabstufung | Goldman | Buy → Sell |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Buy |
| 2020-01-08 | Eingeleitet | SunTrust | Hold |
| 2020-01-07 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2020-01-07 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2019-12-30 | Bestätigt | BTIG Research | Buy |
| 2019-11-05 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2019-10-30 | Bestätigt | BofA/Merrill | Buy |
| 2019-07-02 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-01-30 | Bestätigt | Canaccord Genuity | Buy |
| 2019-01-03 | Eingeleitet | Deutsche Bank | Buy |
| 2019-01-02 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2018-10-16 | Eingeleitet | Barclays | Overweight |
| 2018-08-16 | Eingeleitet | BTIG Research | Buy |
| 2018-06-27 | Eingeleitet | Bernstein | Mkt Perform |
| 2018-04-27 | Bestätigt | Stifel | Buy |
Alle ansehen
Stryker Corp Aktie (SYK) Neueste Nachrichten
Barclays maintains Stryker stock Overweight rating, $443 target - Investing.com
Drug Device Combination Products Market Analysis Report 2025-2030: Discover the Latest Advances and Opportunities - GlobeNewswire Inc.
Here's How Much $1000 Invested In Stryker 20 Years Ago Would Be Worth Today - Benzinga
Stryker tops list of West Michigan’s largest publicly traded companies - Crain's Grand Rapids Business
Jim Cramer on Stryker Corporation (SYK): “I Don’t Like It Enough” - Insider Monkey
Stryker’s SWOT analysis: stock poised for growth amid strategic moves - Investing.com
Stryker corp VP sells shares worth $211,369 - Investing.com Australia
Stryker corp’s chief accounting officer sells $211,369 in shares By Investing.com - Investing.com South Africa
Stryker corp VP sells shares worth $211,369 By Investing.com - Investing.com Nigeria
Stryker corp’s chief accounting officer sells $211,369 in shares - Investing.com Australia
Stryker Hits Treace With Patent Suit Over Surgical Foot-Implants - Bloomberg Law News
Stryker Corporation: Is Its Tuck-in Acquisition Strategy to Ensure Market Leadership In The Med-Tech Landscape? - Smartkarma
Citigroup Raises Price Target for Stryker (SYK) to $455 | SYK Stock News - GuruFocus
Stryker wins FDA clearance for minimally invasive back pain treatment - Yahoo Finance
Stryker (SYK) Price Target Raised by Citi to $455 | SYK Stock Ne - GuruFocus
Stryker (NYSE:SYK) Expands Pain Therapy With FDA Clearance For OptaBlate BVN System - Yahoo Finance
USITC to investigate Fiagon after Stryker medical device infringement claims - MLex
SYK Stock Likely to Rise Following FDA Clearance for OptaBlate System - Yahoo Finance
Stryker Receives FDA Clearance For OptaBlate System Aimed At Low Back Pain Relief: Retail’s Yet To React - Investing.com India
Stryker (SYK) Gains FDA Clearance for OptaBlate System - GuruFocus
Stryker (SYK) Secures FDA Clearance for OptaBlate Nerve Ablation System | SYK Stock News - GuruFocus
Stryker’s new system aims at chronic back pain relief - Investing.com
Breakthrough: FDA Approves Stryker's Revolutionary Nerve Ablation System for Chronic Back Pain Relief - Stock Titan
Stryker Stock: Analyst Estimates & Ratings - Barchart.com
Stryker Inks Deal to Buy One of Its Suppliers Stryker Corp. will pay $150 million for Gaymar Indu - Medical Product Outsourcing
Boston Sci Closes Division Sale to Stryker Corp. On Jan. 3, Boston Scientific Corp. completed the - Medical Product Outsourcing
Stryker Moves to Settle DOJ Probe - Medical Product Outsourcing
Stryker’s Bone Growth Division Sold to Olympus Corp. Stryker Corp. has inked a deal to sell - Medical Product Outsourcing
Insulet Adds Stryker Executive to Board - Medical Product Outsourcing
Former Stryker CEO Receives Lifetime Achievement Award from AdvaMed - Medical Product Outsourcing
Stryker Settles for $80 Million in Unapproved Device Sales Case - Medical Product Outsourcing
Stryker Snaps Up Concentric for $135M - Medical Product Outsourcing
First-Quarter Sales Strong at Stryker Corp. - Medical Product Outsourcing
Stryker: We’re Not Buying Smith & Nephew … Yet, But We’re Interested - Medical Product Outsourcing
SYK Q1 Earnings Call: Stryker Delivers Revenue Beat, Cites International Growth and Tariff Headwinds - Yahoo Finance
Top Executive Sells Stryker Shares in Major Transaction - TipRanks
Stryker Corporation (SYK) Shareholders Approve Key Incentive Pla - GuruFocus
Stryker Corp Shareholders Approve Incentive Plans By Investing.com - Investing.com Nigeria
Stryker at Bank of America 2025 Healthcare Conference: Strategic Growth and Innovation - Investing.com
Stryker Corp Shareholders Approve Incentive Plans - Investing.com
There May Be Reason For Hope In Stryker's (NYSE:SYK) Disappointing Earnings - Yahoo Finance
Stryker: Mako Spine And Shoulder Launching Is On Track (Downgrade To Hold) (NYSE:SYK) - Seeking Alpha
Why Stryker Corporation (SYK) Is Among the Best Medical Device Stocks to Buy Now - Insider Monkey
Stryker Director Makes a Multi-Million Dollar Stock Move! - TipRanks
Stryker declares an $0.84 per share quarterly dividend - Ortho Spine News
Stryker (SYK) Announces Steady Dividend with Promising Growth Forecast - GuruFocus
Stryker raises dividend to $0.84 per share for Q2 - Investing.com
Stryker Declares An $0.84 Per Share Quarterly Dividend - Barchart.com
Here's How Much $100 Invested In Stryker 10 Years Ago Would Be Worth Today - Benzinga
Analysts Offer Insights on Healthcare Companies: Cerus (CERS), Stryker (SYK) and Praxis Precision Medicines (PRAX) - The Globe and Mail
Stryker (SYK) Receives Price Target Boost Following Strong Quart - GuruFocus
Finanzdaten der Stryker Corp-Aktie (SYK)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.01%
1.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):